SHANGHAI, November 2, 2026 — Ractigen Therapeutics has begun a Phase II clinical trial of RAG-01, an experimental therapy for non-muscle invasive bladder cancer, with the first site initiation meeting held at Fudan University Shanghai Cancer Center. The study will test the drug alone and in combination with the chemotherapy agent mitomycin C in patients with intermediate- or high-risk forms of the disease.
For patients, the distinction matters. Non-muscle invasive bladder cancer sits in the lining of the bladder and has not reached the muscle wall, which is why doctors can often treat it without removing the organ. The trade-off is that it comes back. High-risk patients in particular face a substantial risk of tumor recurrence and of the cancer progressing to muscle-invasive disease, according to Ractigen, and that risk is what has driven the search for stronger bladder-sparing regimens.
What the Trial Will Measure
The RAG010201 study is designed as a randomized, controlled, multi-center Phase II trial. It will evaluate efficacy, safety, tolerability and pharmacokinetics, the way the body processes the drug, for intravesical RAG-01, meaning the therapy is delivered into the bladder. The trial includes a safety run-in phase to establish the recommended dosing regimen before the randomized portion begins.
It is split into two cohorts by risk level. Cohort A covers high-risk patients and will compare RAG-01 on its own against RAG-01 plus mitomycin C. After the safety run-in, that cohort moves to an open-label, 1:1 randomized phase with the 24-month event-free survival rate as the primary endpoint. In plain terms, researchers want to know how many patients are still free of recurrence or progression two years out, and whether the combination does better than the single drug.
Eleven Hospitals, One Senior Investigator
The trial is led by Professor Ding-Wei Ye, a urologic oncologist at Fudan University Shanghai Cancer Center and chief expert of the hospital’s urologic oncology multidisciplinary team. Eleven medical institutions across China are taking part, among them Peking University First Hospital, Ruijin Hospital in Shanghai, Hunan Cancer Hospital, Nanjing Drum Tower Hospital, Qilu Hospital of Shandong University and Sun Yat-sen Memorial Hospital in Guangzhou.
That footprint is one of the more practical details for families. A multi-center design means patients are enrolled closer to home rather than traveling to a single research hospital, and it pools enough cases to produce results faster than any one site could on its own.
The Science Behind the Shot
RAG-01 belongs to a class called small activating RNA, or saRNA. Most RNA medicines people have heard of work by switching a gene off. saRNA does the opposite: it is designed to switch a gene back on. Ractigen has described RAG-01 as a first-in-class saRNA therapeutic, and the bladder is a useful place to try one, because the drug can be instilled directly into the organ rather than traveling through the whole body.
The delivery technology behind it got a public airing less than two weeks ago. On October 23, the company published a peer-reviewed study in Molecular Therapy – Nucleic Acids describing its LiCO delivery platform, which is designed to carry oligonucleotides into tissues beyond the liver. Ractigen said the platform has been clinically validated across both systemic and local routes through its ongoing programs, naming RAG-18 for Duchenne muscular dystrophy and RAG-01 for bladder cancer.
What This Does Not Show Yet
No efficacy results from this trial have been released. A Phase II study of this size and design can show whether the drug is safe and whether it produces signals of benefit, but it cannot establish that patients live longer. The 24-month event-free survival endpoint will take two years of follow-up to mature, and the trial is only now beginning enrollment at its sites.
The earlier preclinical work on the delivery platform, published in mice and non-human primates, is not evidence that RAG-01 works in people. Patients with intermediate- or high-risk non-muscle invasive bladder cancer should ask their urologist or oncologist whether any clinical trial, in China or closer to home, fits their stage and history. That conversation is the right first step, not a news release.
Sources
- Ractigen Therapeutics Kicks Off Multi-Center Phase II Clinical Trial of First-in-Class saRNA Therapeutic RAG-01 for Non-Muscle Invasive Bladder Cancer
- Ractigen Therapeutics Kicks Off Multi-Center Phase II Clinical Trial of First-in-Class saRNA Therapeutic RAG-01 for Non-Muscle Invasive Bladder Cancer
- Ractigen Therapeutics Kicks Off Multi-Center Phase II Clinical Trial of First-in-Class saRNA Therapeutic RAG-01 for Non-Muscle Invasive Bladder Cancer
- Ractigen Therapeutics Publishes Foundational Study on its Extrahepatic LiCO™ Delivery Platform in Molecular Therapy – Nucleic Acids
- Ractigen Therapeutics Kicks Off Multi-Center Phase II Clinical Trial of First-in-Class saRNA Therapeutic RAG-01 for Non-Muscle Invasive Bladder Cancer
Photo: National Cancer Institute / Unsplash (Unsplash License)
